Catalist-listed iX Biopharma has announced that its novel Wafermine sublingual ketamine wafers will be used in a study to evaluate its use as a treatment for pain suffered by patients with advanced cancer.

The pilot study will be funded by Chris O’Brien Lifehouse, a comprehensive cancer hospital in Camperdown, Sydney.

The study is a prospective double-blind randomised placebo-controlled repeated cross-over trial and will be carried out at 2 sites, Chris O’Brien Lifehouse cancer centre and Royal Prince Alfred Hospital. It will enrol 32 adult patients with locally advanced or metastatic cancer who experience moderate to severe pain associated with cancer diagnosis requiring ongoing opioid analgesia. The study objectives include the measurement of pain severity, pain impact, side effects and quality of life. 

To continue reading,

Sign in to access this Premium article.

Subscription entitlements:

Less than $9 per month
3 Simultaneous logins across all devices
Unlimited access to latest and premium articles
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)

Related Stories

Stay updated with Singapore corporate news stories for FREE

Follow our Telegram | Facebook